Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04610138 | Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants | PHASE2 | COMPLETED | 296 | — | — | Jun 1, 2021 | Oct 20, 2022 | Apr 3, 2023 | 5 | Brazil |
Time to substantial alleviation of COVID-19 symptoms up to 28-days, over a continuous period ≥ 48 hours (confirmed symptom resolution), defined as PGI-Severity of 'Normal' in Participants whose Baseline PGI-Severity value was 'Mild'; or, a PGI-Severity of 'Normal' or 'Mild' in participants whose Baseline PGI-Severity value was 'Moderate' or 'Severe'.
| Arm | Type | Description |
|---|---|---|
| Active treatment with 60 ml low-dose ZnAg | EXPERIMENTAL | (Zn 6 ug/ml and Ag 10 ug/ml; equivalent to 0.6 mg Ag, 0.36 mg Zn), po q12 hours |
| Active treatment with 60 ml high-dose ZnAg | EXPERIMENTAL | (Zn 12 ug/ml and Ag 20 ug/ml; equivalent to 1.2 mg Ag, 0.72 mg Zn), po q12 hours; |
| 60 ml matching placebo | PLACEBO_COMPARATOR | 60 ml matching placebo, po q12 hours |
| Name | Type | Description |
|---|---|---|
| CNM-ZnAg | DRUG | ZnAg liquid solution |
| Placebo | DRUG | Water |
Inclusion Criteria: 1. Adults, aged 40 - 90 years (inclusive) 2. Acute onset (within 96 hours of the Baseline visit) of two or more COVID-19 symptoms self-rated as moderate-to-severe, including fever, myalgia, fatigue, chest tightness, chills, cough, diarrhea, gastrointestinal distress, headache, s...